載入中
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
前收盤價
US$10.18
−US$0.18 · -1.74%
盤前
US$10.05
−US$0.13 · -1.28%
10月13日 上午4:11 ET
盤中時間採用ET。市場資料可能有所延遲。
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
日內區間
目前US$10.18
52週區間
目前US$10.18
盤中時間採用ET。市場資料可能有所延遲。
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
日內區間
目前US$10.18
52週區間
目前US$10.18
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 5.1億 USD | 4.26億 USD | 2.58億 USD | 1.54億 USD | 8094.3萬 USD |
| 銷貨成本 | 2.17億 USD | 2.07億 USD | 1.69億 USD | 1.19億 USD | 7977萬 USD |
| 毛利 | 2.93億 USD | 2.2億 USD | 8894.2萬 USD | 3526.5萬 USD | 117.3萬 USD |
| 研究與開發 | 476.2萬 USD | 181.3萬 USD | 330萬 USD | 361.4萬 USD | 364.6萬 USD |
| 銷售、一般及管理費用 | 9158萬 USD | 7412.4萬 USD | 5902萬 USD | 5245.8萬 USD | 4289.7萬 USD |
| 營業費用 | 1.01億 USD | 8057萬 USD | 6731萬 USD | 7463萬 USD | 5954.7萬 USD |
| 利息收入 | 187.1萬 USD | 209.7萬 USD | 161.7萬 USD | 4.48萬 USD | 3.45萬 USD |
| 利息支出 | 711萬 USD | 1393萬 USD | 2502.7萬 USD | 1927.94萬 USD | 1305.68萬 USD |
| 折舊和攤銷 | 809.6萬 USD | 804.5萬 USD | 833.2萬 USD | 711.34萬 USD | 549.55萬 USD |
| 營業利益 | 1.91億 USD | 1.39億 USD | 2163.2萬 USD | −3936.5萬 USD | −5837.4萬 USD |
| 淨利 | 1.47億 USD | 1.98億 USD | −2823.9萬 USD | −6590.4萬 USD | −7164.8萬 USD |
公司資料更新於 2026年10月13日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
報告持有此股票曝險的交易所交易基金。
First Trust NYSE Arca Biotechnology Index FundFBT1.03億3.57%28.91億 USD0.55%US$263.9-0.57%
Vanguard Morningstar Total Stock Market ETFVTI6612.07萬0.00%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM6229.97萬0.08%787.4億 USD0.19%US$277.9-0.37%
State Street SPDR S&P Biotech ETFXBI4624.76萬0.47%103.03億 USD0.35%US$151.4-1.54%
Vanguard Extended Market ETFVXF2523.45萬0.03%954億 USD0.05%US$233.52-0.63%
Vanguard Morningstar Small-Cap ETFVB2377.42萬0.01%1853億 USD0.03%US$288.16-0.46%
iShares Russell 2000 Growth ETFIWO2209.8萬0.16%139.17億 USD0.24%US$353.71-0.86%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM2126.09萬0.13%157.12億 USD0.03%US$53.42-0.06%First Trust NYSE Arca Biotechnology Index FundFBTVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 Growth ETFIWOState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
